Second‐line chimeric antigen receptor T‐cell therapy versus standard of care in relapsed or refractory large B‐cell lymphoma: A systematic review and meta‐analysis

Ähnliche Einträge

• Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy
  von: Xiuyong Dang, et al.
  Veröffentlicht: (2024)
• Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration
  von: Alice Sýkorová, et al.
  Veröffentlicht: (2024)
• Correction to “Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy”
  Veröffentlicht: (2025)
• Concerns regarding stem cell mobilization in liposomal mitoxantrone therapy for relapsed/refractory T‐cell/natural killer‐cell lymphomas
  von: Xia Zhao, et al.
  Veröffentlicht: (2025)
• Advances in research on factors affecting chimeric antigen receptor T‐cell efficacy
  von: Delian Zhou, et al.
  Veröffentlicht: (2024)